John Gordon Freund M.D.

Background

Dr. John Gordon Freund, M.D., has been the Managing Director of Skyline Ventures since 1997. Dr. Freund serves as the Managing Director of Skyline Ventures III, L.P., Skyline V, L.P. and Skyline Ventures IV, L.P. He has a considerable experience at most of the major sectors of the healthcare investment market including medical devices, information technology, small molecule chemistry and biochips and protein therapeutics, biotechnology, diagnostics, and healthcare services. ... Prior to co-founding the Skyline Ventures in 1997, he was with a Private Equity Group from 1995 to 1997 including served as its Chancellor Capital Management as the Managing Director and West Coast Partner. He co-founded Intuitive Surgical, Inc. in 1995 and raised its initial venture capital. Previously, he was with Acuson Corporation from 1988 to 1994. He served as Executive Vice President and Senior Executive of Acuson Corporation. From 1982 to 1988, Dr. Freund was a general partner at Morgan Stanley & Co., where he co-founded the Healthcare Group in the Corporate Finance Department in 1983. He was a general partner of Morgan Stanley Venture Partners from 1987 to 1988. He was involved in founding, financing, managing, and advising healthcare companies since 1982. He serves as the Chairman of Calypso Medical Technologies, Inc. He co-founded Marquis Tech Holdings, Inc., in 1998 and served as its Chairman. He has been an Independent Director of MAKO Surgical Corp., since October 2008. Dr. Freund has been Director of Tetraphase Pharmaceuticals, Inc. since October 23, 2012. He has been Independent Director of Smallcap World Fund, Inc - Smallcap World Fund since 2000. He has been a Director at Collegium Pharmaceutical, Inc. and Proteon Therapeutics, Inc. since February 2014. He has been an Independent Director of Xenoport Inc., since 1999 and has been its Lead Director since July 30, 2008. He serves as a Director of Advion, Inc.; Sutro Biopharma, Inc.; Crescendo Bioscience and Triad Therapeutics, Inc. He has been an Independent Director of Concert Pharmaceuticals, Inc. since December 2013. Dr. Freund serves as a Director of Satiety, Inc. He has been a Director of American Funds and its Funds Complex since 2000. He has been a Director at SI-Bone Inc. since January 7, 2013. He serves as a Director of three mutual funds managed by Capital Research and Management. He serves as a Member of the Advisory Board for the Harvard Business School Healthcare Initiative. He is a Member of the Therapeutics Advisory Council of Harvard Medical School. He served as a Director of Sirtris Pharmaceuticals, Inc. from 2004 to 2008. He served as a Director of Reconstructive Technologies, Inc. and DiscoveRx Corporation. He served as a Director of Marquis Tech Holdings, Inc. He served as a Director at LJL BioSystems, Inc., since June 1997. He served as a Director of Allos Therapeutics, Inc. He served as a Director of MediVance, Inc, Tolerx, Inc., Vitra Bioscience, Inc. and Alteer Corporation. He served as a Director of Hansen Medical, Inc., from November 2002 to March 15, 2010. He served as a Director of Zyomyx, Inc. and Roche NimbleGen, Inc. Dr. Freund served as a Director of MAP Pharmaceuticals, Inc. from August 2004 to October 16, 2011 and Intuitive Surgical until 2000. He was the co-author of The Official MBA Handbook. He won the Loeb Fellowship in Finance at Harvard Business School. He won Entrepreneur of the Year Award. Dr. Freund holds an MBA from Harvard Business School, an MD from Harvard Medical School and a BA in history from Harvard College.

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.